Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Phathom Pharmaceuticals, Inc.PHAT · Entity 5177 | Director · President and CEO | February 10, 2026 | February 12, 2026 |
| VIVEVE MEDICAL, INC.VIVE · Entity 11899 | Director | January 03, 2023 | January 05, 2023 |
| Yarrow Bioscience, Inc.VYNE · Entity 6871 | Director | December 12, 2025 | December 15, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Phathom Pharmaceuticals, Inc.
Report date February 10, 2026 · Filed February 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 379,592 |
Reported balance
After 2026-02-10 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-02-10 · Grant · Acquired 12,362 · Balance 379,592 F1: Represents shares issued upon vesting of performance stock units granted to the reporting person on April 3, 2025 based on the achievement of performance criteria determined to be satisfied on February 10, 2026. F2: Includes 2,410 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in January 2026. |
| Common StockSEC Table I · non-derivative | Direct | 373,315 |
Reported balance
After 2026-02-10 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-02-10 · Tax withholding · Disposed 6,277 · Balance 373,315 F3: Represents shares underlying the performance stock units that were surrendered by the reporting person to the Issuer in satisfaction of the Issuer's tax withholding obligation. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares issued upon vesting of performance stock units granted to the reporting person on April 3, 2025 based on the achievement of performance criteria determined to be satisfied on February 10, 2026.
F2: Includes 2,410 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in January 2026.
F3: Represents shares underlying the performance stock units that were surrendered by the reporting person to the Issuer in satisfaction of the Issuer's tax withholding obligation.
VIVEVE MEDICAL, INC.
Report date January 03, 2023 · Filed January 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 72,000 |
Reported balance
After 2023-01-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-01-03 · Grant · Acquired 72,000 · Balance 72,000 F1: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's common stock. F2: The RSUs vest in full on the earlier of December 1, 2023 or the closing of a Sale Event (as defined in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan), subject to the reporting person's continuous service to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's common stock.
F2: The RSUs vest in full on the earlier of December 1, 2023 or the closing of a Sale Event (as defined in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan), subject to the reporting person's continuous service to the Issuer.
Yarrow Bioscience, Inc.
Report date December 12, 2025 · Filed December 15, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.38 · Expires 2035-12-11 | Direct | 20,000 |
Reported balance
After 2025-12-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-12 · Grant · Acquired 20,000 · Balance 20,000 F1: Represents the annual award to non-employee directors of the Issuer, awarded on the date of the Issuer's annual meeting of stockholders. The shares subject to the option vest on December 12, 2026, subject to the Reporting Person's continuous service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the annual award to non-employee directors of the Issuer, awarded on the date of the Issuer's annual meeting of stockholders. The shares subject to the option vest on December 12, 2026, subject to the Reporting Person's continuous service through such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
KalVista Pharmaceuticals, Inc.
Report date November 21, 2016 · Filed November 22, 2016
Section 16 reporting ended · disclosed 2016-11-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2016-11-21 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2016-11-21 · Exercise / conversion · Acquired 1,125 · Balance 1,125 F1: The transactions reported in this Form 4 were completed pursuant to the consummation of the actions contemplated in that certain Share Purchase Agreement, dated as of June 15, 2016, by and among Carbylan, KalVista Pharmaceuticals Ltd. ("KalVista"), the shareholders of KalVista, and T. Andrew Crockett as the Seller Representative (the "Transaction"), and reflect a 14 to 1 reverse stock split completed immediately prior to the closing of the Transaction. Row 2 · 2016-11-21 · Tax withholding · Disposed 1,026 · Balance 99 F1: The transactions reported in this Form 4 were completed pursuant to the consummation of the actions contemplated in that certain Share Purchase Agreement, dated as of June 15, 2016, by and among Carbylan, KalVista Pharmaceuticals Ltd. ("KalVista"), the shareholders of KalVista, and T. Andrew Crockett as the Seller Representative (the "Transaction"), and reflect a 14 to 1 reverse stock split completed immediately prior to the closing of the Transaction. Row 3 · 2016-11-21 · Other · Disposed 99 · Balance 0 F1: The transactions reported in this Form 4 were completed pursuant to the consummation of the actions contemplated in that certain Share Purchase Agreement, dated as of June 15, 2016, by and among Carbylan, KalVista Pharmaceuticals Ltd. ("KalVista"), the shareholders of KalVista, and T. Andrew Crockett as the Seller Representative (the "Transaction"), and reflect a 14 to 1 reverse stock split completed immediately prior to the closing of the Transaction. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.84 · Expires 2023-06-06 | Direct | 0 |
Reported balance
After 2016-11-21 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2016-11-21 · Exercise / conversion · Acquired 1,125 · Balance 0 F1: The transactions reported in this Form 4 were completed pursuant to the consummation of the actions contemplated in that certain Share Purchase Agreement, dated as of June 15, 2016, by and among Carbylan, KalVista Pharmaceuticals Ltd. ("KalVista"), the shareholders of KalVista, and T. Andrew Crockett as the Seller Representative (the "Transaction"), and reflect a 14 to 1 reverse stock split completed immediately prior to the closing of the Transaction. F2: The option is fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 were completed pursuant to the consummation of the actions contemplated in that certain Share Purchase Agreement, dated as of June 15, 2016, by and among Carbylan, KalVista Pharmaceuticals Ltd. ("KalVista"), the shareholders of KalVista, and T. Andrew Crockett as the Seller Representative (the "Transaction"), and reflect a 14 to 1 reverse stock split completed immediately prior to the closing of the Transaction.
F2: The option is fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 10, 2026 Filed Feb 12, 2026 16:34 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | Tax withholdingCommon Stock | 6,277 | $12.82 | $80,471.14 |
DisclosureSEC source: 0001193125-26-048867 · ownership.xml · nonDerivative · entry 2 Basta Steven L · CIK 0001417397 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 373,315 F3 · kind: Represents shares underlying the performance stock units that were surrendered by the reporting person to the Issuer in satisfaction of the Issuer's tax withholding obligation. Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 16:34 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantCommon Stock | 12,362 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-048867 · ownership.xml · nonDerivative · entry 1 Basta Steven L · CIK 0001417397 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 379,592 F1 · shares: Represents shares issued upon vesting of performance stock units granted to the reporting person on April 3, 2025 based on the achievement of performance criteria determined to be satisfied on February 10, 2026. F2 · balance_after: Includes 2,410 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in January 2026. Read SEC document |
| January 02, 2026 Filed Jan 2, 2026 17:46 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantStock Option (Right to Buy) · Derivative | 226,156 | $0.00 Strike: $15.71 | $0.00 |
DisclosureSEC source: 0001193125-26-001127 · ownership.xml · derivative · entry 2 Basta Steven L · CIK 0001417397 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 221,156 Underlying: Common Stock · 226,156 shares Expires 2036-01-01 F2 · derivative.exercise_date: 1/48th of the total number of shares of common stock subject to the option vest monthly following the Vesting Commencement Date, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| January 02, 2026 Filed Jan 2, 2026 17:46 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantCommon Stock | 251,034 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-001127 · ownership.xml · nonDerivative · entry 1 Basta Steven L · CIK 0001417397 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 364,820 F1 · shares: Represents restricted stock units ("RSUs") granted on January 2, 2026. 1/3 of the total number of RSUs granted vest on each of the first three anniversaries of January 2, 2026, the vesting commencement date (the "Vesting Commencement Date"), subject to the Reporting Person's continued service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 17:45 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | Tax withholdingCommon Stock | 31,502 | $15.36 | $483,870.72 |
DisclosureSEC source: 0001193125-25-327126 · ownership.xml · nonDerivative · entry 2 Basta Steven L · CIK 0001417397 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,786 F2 · kind: Represents shares underlying the performance stock units that were surrendered by the reporting person to the Issuer in satisfaction of the Issuer's tax withholding obligation. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 17:45 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantCommon Stock | 62,038 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-327126 · ownership.xml · nonDerivative · entry 1 Basta Steven L · CIK 0001417397 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145,288 F1 · shares: Represents shares issued upon vesting of performance stock units granted to the reporting person on April 3, 2025 based on the achievement of performance criteria determined to be satisfied on December 17, 2025. Read SEC document |
| December 12, 2025 Filed Dec 15, 2025 16:15 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001417397-25-000004 · form4-12152025_041203.xml · derivative · entry 1 Basta Steven L · CIK 0001417397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2035-12-11 F1 · derivative.exercise_date: Represents the annual award to non-employee directors of the Issuer, awarded on the date of the Issuer's annual meeting of stockholders. The shares subject to the option vest on December 12, 2026, subject to the Reporting Person's continuous service through such date. Read SEC document |
| November 28, 2025 Filed Dec 2, 2025 18:45 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | Exercise / conversionPerformance Shares · Derivative | 90,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-305575 · ownership.xml · derivative · entry 3 Basta Steven L · CIK 0001417397 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 90,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of common stock of the Issuer. F3 · derivative.exercise_date: On April 3, 2025, the reporting person was granted 360,000 performance stock units, of which 90,000 vested on September 25, 2025 and an additional 90,000 vested on November 28, 2025, in each case due to the achievement of the applicable stock price hurdle. The remaining performance stock units will vest based on the achievement of stock price hurdles over a period of four years following the grant date, subject to the reporting person's continued service through the date each such stock price hurdle is achieved. F3 · derivative.expiration_date: On April 3, 2025, the reporting person was granted 360,000 performance stock units, of which 90,000 vested on September 25, 2025 and an additional 90,000 vested on November 28, 2025, in each case due to the achievement of the applicable stock price hurdle. The remaining performance stock units will vest based on the achievement of stock price hurdles over a period of four years following the grant date, subject to the reporting person's continued service through the date each such stock price hurdle is achieved. Read SEC document |
| November 28, 2025 Filed Dec 2, 2025 18:45 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | Tax withholdingCommon Stock | 48,375 | $15.62 | $755,617.50 |
DisclosureSEC source: 0001193125-25-305575 · ownership.xml · nonDerivative · entry 2 Basta Steven L · CIK 0001417397 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,250 F1 · kind: Represents shares underlying the performance stock units that were surrendered by the reporting person to the Issuer in satisfaction of the Issuer's tax withholding obligation. Read SEC document |
| November 28, 2025 Filed Dec 2, 2025 18:45 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | Exercise / conversionCommon Stock | 90,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-305575 · ownership.xml · nonDerivative · entry 1 Basta Steven L · CIK 0001417397 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 25, 2025 Filed Sep 26, 2025 19:03 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | Exercise / conversionPerformance Shares · Derivative | 90,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-220950 · ownership.xml · derivative · entry 3 Basta Steven L · CIK 0001417397 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 270,000 Underlying: Common Stock · 90,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of common stock of the Issuer. F3 · derivative.exercise_date: On April 3, 2025, the reporting person was granted 360,000 performance stock units, of which 90,000 vested on September 25, 2025 due to the achievement of the applicable stock price hurdle. The remaining performance stock units will vest based on the achievement of stock price hurdles over a period of four years following the grant date, subject to the reporting person's continued service through the date each such stock price hurdle is achieved. F3 · derivative.expiration_date: On April 3, 2025, the reporting person was granted 360,000 performance stock units, of which 90,000 vested on September 25, 2025 due to the achievement of the applicable stock price hurdle. The remaining performance stock units will vest based on the achievement of stock price hurdles over a period of four years following the grant date, subject to the reporting person's continued service through the date each such stock price hurdle is achieved. Read SEC document |
| September 25, 2025 Filed Sep 26, 2025 19:03 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | Tax withholdingCommon Stock | 48,375 | $11.66 | $564,052.50 |
DisclosureSEC source: 0001193125-25-220950 · ownership.xml · nonDerivative · entry 2 Basta Steven L · CIK 0001417397 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,625 F1 · kind: Represents shares underlying the performance stock units that were surrendered by the reporting person to the Issuer in satisfaction of the Issuer's tax withholding obligation. Read SEC document |
| September 25, 2025 Filed Sep 26, 2025 19:03 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | Exercise / conversionCommon Stock | 90,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-220950 · ownership.xml · nonDerivative · entry 1 Basta Steven L · CIK 0001417397 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 03, 2025 Filed Apr 3, 2025 17:30 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantStock Option (Right to Buy) · Derivative | 1,085,000 | $0.00 Strike: $5.01 | $0.00 |
DisclosureSEC source: 0000950170-25-050621 · ownership.xml · derivative · entry 2 Basta Steven L · CIK 0001417397 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,085,000 Underlying: Common Stock · 1,085,000 shares Expires 2035-04-02 F3 · derivative.exercise_date: The stock option will vest with respect to 25% of the shares of common stock on April 3, 2026, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates. Read SEC document |
| April 03, 2025 Filed Apr 3, 2025 17:30 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantPerformance Shares · Derivative | 360,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-050621 · ownership.xml · derivative · entry 1 Basta Steven L · CIK 0001417397 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 360,000 Underlying: Common Stock · 360,000 shares Expires not disclosed F1 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of common stock of the Issuer. F2 · derivative.exercise_date: The performance stock units will vest based on the achievement of stock price hurdles and service-based vesting requirements over a period of four years following the grant date. F2 · derivative.expiration_date: The performance stock units will vest based on the achievement of stock price hurdles and service-based vesting requirements over a period of four years following the grant date. Read SEC document |
| December 12, 2024 Filed Dec 13, 2024 16:15 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001415889-24-029288 · form4-12132024_041211.xml · derivative · entry 1 Basta Steven L · CIK 0001417397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2034-12-11 F1 · derivative.exercise_date: Represents the annual award to non-employee directors of the Issuer, awarded on the date of the Issuer's annual meeting of stockholders. The shares subject to the option vest on December 12, 2025, subject to the Reporting Person's continuous service through such date. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 17:10 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.33 | $0.00 |
DisclosureSEC source: 0001209191-24-000460 · doc4.xml · derivative · entry 1 Basta Steven L · CIK 0001417397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-12-31 F1 · derivative.exercise_date: The shares subject to the option vest on January 1, 2025, subject to the Reporting Person's continuous service through such date. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 17:02 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.70 | $0.00 |
DisclosureSEC source: 0001209191-23-058809 · doc4.xml · derivative · entry 1 Basta Steven L · CIK 0001417397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-12-12 F1 · derivative.exercise_date: Represents the annual award to non-employee directors of the Issuer, awarded on the date of the Issuer's annual meeting of stockholders. These options vest on December 13, 2024, subject to the Reporting Person's continuous service through such date. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 16:04 UTC | VIVEVE MEDICAL, INC. VIVE · Entity 11899 | GrantRestricted Stock Unit · Derivative | 72,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-000485 · rdgdoc.xml · derivative · entry 1 Basta Steven L · CIK 0001417397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,000 Underlying: Common Stock · 72,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs vest in full on the earlier of December 1, 2023 or the closing of a Sale Event (as defined in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan), subject to the reporting person's continuous service to the Issuer. F2 · derivative.expiration_date: The RSUs vest in full on the earlier of December 1, 2023 or the closing of a Sale Event (as defined in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan), subject to the reporting person's continuous service to the Issuer. Read SEC document |
| August 10, 2022 Filed Aug 12, 2022 17:10 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantStock Options · Derivative | 20,500 | $0.00 Strike: $0.31 | $0.00 |
DisclosureSEC source: 0001209191-22-045649 · doc4.xml · derivative · entry 1 Basta Steven L · CIK 0001417397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,500 Underlying: Common Stock · 20,500 shares Expires 2032-08-10 F1 · derivative.exercise_date: Represents the annual award to non-executive directors of the Issuer, awarded on the date of the Issuer's annual meeting of stockholders. These options vest over a 12-month period in equal, monthly installments, ending August 10, 2023. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 16:02 UTC | VIVEVE MEDICAL, INC. VIVE · Entity 11899 | GrantNon-Qualified Stock Option (Right to Purchase) · Derivative | 48,000 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0001437749-22-000544 · rdgdoc.xml · derivative · entry 1 Basta Steven L · CIK 0001417397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,000 Underlying: Common Stock · 48,000 shares Expires 2032-01-03 F1 · derivative.exercise_date: The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan, as amended (the "2013 Plan") and received 48,000 non-qualified stock options on January 4, 2022 (the "Grant Date"). The non-qualified stock options shall vest and become exercisable in 48 equal monthly installments from the Grant Date. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 16:03 UTC | VIVEVE MEDICAL, INC. VIVE · Entity 11899 | Disposition to issuerCommon Stock | 28 | $1.41 | $39.48 |
DisclosureSEC source: 0001437749-21-028891 · rdgdoc.xml · nonDerivative · entry 1 Basta Steven L · CIK 0001417397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.415 to $1.4001. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 19, 2021 Filed Jul 20, 2021 17:04 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantStock Options · Derivative | 20,500 | $0.00 Strike: $2.75 | $0.00 |
DisclosureSEC source: 0001209191-21-047406 · doc4.xml · derivative · entry 1 Basta Steven L · CIK 0001417397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,500 Underlying: Common Stock · 20,500 shares Expires 2031-07-19 F1 · derivative.exercise_date: These options vest over a 12 month period in equal, monthly installments, ending July 19, 2022. Read SEC document |
| June 23, 2021 Filed Jun 25, 2021 16:07 UTC | VIVEVE MEDICAL, INC. VIVE · Entity 11899 | GrantNon-Qualified Stock Option (Right to Purchase) · Derivative | 116,200 | $0.00 Strike: $2.73 | $0.00 |
DisclosureSEC source: 0001437749-21-015660 · rdgdoc.xml · derivative · entry 1 Basta Steven L · CIK 0001417397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,200 Underlying: Common Stock · 116,200 shares Expires 2031-06-22 F1 · derivative.exercise_date: The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan (the "Plan") and received 116,200 non-qualified stock options on June 23, 2021 (the "Grant Date"). The non-qualified stock options shall vest and become exercisable in 48 equal monthly installments from the Grant Date. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 19:15 UTC | VIVEVE MEDICAL, INC. VIVE · Entity 11899 | GrantRestricted Stock Unit · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-21-001108 · rdgdoc.xml · derivative · entry 1 Basta Steven L · CIK 0001417397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan and received 50,000 RSUs on January 20, 2021 (the "Grant Date"). The RSUs vest in full on the second anniversary of the Grant Date. F2 · derivative.expiration_date: The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan and received 50,000 RSUs on January 20, 2021 (the "Grant Date"). The RSUs vest in full on the second anniversary of the Grant Date. Read SEC document |
| September 21, 2020 Filed Sep 22, 2020 11:04 UTC | VIVEVE MEDICAL, INC. VIVE · Entity 11899 | GrantNon-Qualified Stock Option (Right to Purchase) · Derivative | 165,000 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001437749-20-019986 · rdgdoc.xml · derivative · entry 1 Basta Steven L · CIK 0001417397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,000 Underlying: Common Stock · 165,000 shares Expires 2030-09-20 F1 · derivative.exercise_date: The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan (the "Plan") and received 165,000 non-qualified stock options on September 21, 2020 (the "Grant Date"). The non-qualified stock options shall vest in full on the first anniversary of the Grant Date. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 16:38 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantStock Options · Derivative | 22,500 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0001209191-20-045129 · doc4.xml · derivative · entry 1 Basta Steven L · CIK 0001417397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2030-08-03 F1 · derivative.exercise_date: These options vest over a 12 month period in equal, quarterly installments, ending August 3, 2021. Read SEC document |
| April 03, 2020 Filed Apr 7, 2020 17:19 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantCommon Stock | 14,499 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-023799 · doc4.xml · nonDerivative · entry 1 Basta Steven L · CIK 0001417397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 536,537 F1 · price: As disclosed by the Issuer in its Current Report on Form 8-K filed with the Securities and Exchange Commission on April 6, 2020, following the receipt of certain clinical trial results, Menlo Therapeutics Inc. ("Menlo") issued additional shares of its common stock pursuant to certain contingent stock rights ("CSRs") issued in connection with the March 9, 2020 merger (the "Merger") of Menlo and Foamix Pharmaceuticals Ltd. ("Foamix"), including pursuant to CSRs held by the Reporting Person. The issuance of shares pursuant to the CSRs resulted in an adjustment to the effective exchange ratio applicable to the Merger, from 0.5924 to 1.8006 (the "Final Exchange Ratio"). Menlo derivative securities issued in exchange for Foamix derivative securities in connection with the Merger were also adjusted pursuant to their terms to give effect to the Final Exchange Ratio. The transactions reported in these line items reflect the additional shares. Read SEC document |
| March 19, 2020 Filed Mar 23, 2020 16:44 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantStock Option · Derivative | 45,000 | $0.00 Strike: $2.67 | $0.00 |
DisclosureSEC source: 0001209191-20-020657 · doc4.xml · derivative · entry 1 Basta Steven L · CIK 0001417397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2030-03-19 F1 · derivative.exercise_date: The option will vest and become exercisable as to 1/3rd of the shares subject to the option on each annual anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 17:55 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantCommon Stock | 7,108 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-018221 · doc4.xml · nonDerivative · entry 1 Basta Steven L · CIK 0001417397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 522,038 F1 · price: Received in the merger of Foamix Pharmaceuticals Ltd. ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. ("Menlo"), in exchange for 12,000 Foamix ordinary shares. The closing price of a Foamix ordinary share on March 6, 2020, the last trading day before such merger, was $2.99. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, which may entitle the Reporting Person to certain additional Menlo equity securities as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020. F2 · balance_after: Includes 5,166 shares of Menlo common stock acquired pursuant to the Menlo Therapeutics Inc. Employee Stock Purchase Plan and Rule 16b-3(c). Read SEC document |
| December 11, 2019 Filed Dec 13, 2019 21:54 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | Exercise / conversionNon-Qualified Stock Option · Derivative | 14,000 | $1.83 | $25,620.00 |
DisclosureSEC source: 0000899243-19-029185 · doc4.xml · derivative · entry 5 Basta Steven L · CIK 0001417397 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 357,641 Underlying: Common Stock · 14,000 shares Expires 2026-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Non-Qualified Stock Option was exercised and the shares were acquired in order to mitigate potential negative tax consequences to both the Issuer and the Reporting Person under Section 280G and 4999 of the Internal Revenue Code. Read SEC document |
| December 11, 2019 Filed Dec 13, 2019 21:54 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | Exercise / conversionRestricted Stock Units · Derivative | 238,800 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-029185 · doc4.xml · derivative · entry 4 Basta Steven L · CIK 0001417397 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 238,800 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On July 29, 2019, the Reporting Person was granted 238,800 restricted stock units ("RSUs"), for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. The RSUs were scheduled to vest in two (2) equal annual installments beginning July 29, 2020. The vesting of the RSUs was accelerated in full on December 11, 2019 in connection with the pending transactions contemplated by the Agreement and Plan of Merger entered into on November 10, 2019 among the Issuer, Foamix Pharmaceuticals Ltd and Giants Merger Subsidiary Ltd., a wholly-owned subsidiary of the Issuer, in order to mitigate potential negative tax consequences to both the Issuer and the Reporting Person under Section 280G and 4999 of the Internal Revenue Code. F1 · derivative.exercise_date: On July 29, 2019, the Reporting Person was granted 238,800 restricted stock units ("RSUs"), for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. The RSUs were scheduled to vest in two (2) equal annual installments beginning July 29, 2020. The vesting of the RSUs was accelerated in full on December 11, 2019 in connection with the pending transactions contemplated by the Agreement and Plan of Merger entered into on November 10, 2019 among the Issuer, Foamix Pharmaceuticals Ltd and Giants Merger Subsidiary Ltd., a wholly-owned subsidiary of the Issuer, in order to mitigate potential negative tax consequences to both the Issuer and the Reporting Person under Section 280G and 4999 of the Internal Revenue Code. F1 · derivative.expiration_date: On July 29, 2019, the Reporting Person was granted 238,800 restricted stock units ("RSUs"), for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. The RSUs were scheduled to vest in two (2) equal annual installments beginning July 29, 2020. The vesting of the RSUs was accelerated in full on December 11, 2019 in connection with the pending transactions contemplated by the Agreement and Plan of Merger entered into on November 10, 2019 among the Issuer, Foamix Pharmaceuticals Ltd and Giants Merger Subsidiary Ltd., a wholly-owned subsidiary of the Issuer, in order to mitigate potential negative tax consequences to both the Issuer and the Reporting Person under Section 280G and 4999 of the Internal Revenue Code. Read SEC document |
| December 11, 2019 Filed Dec 13, 2019 21:54 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | Exercise / conversionCommon stock | 14,000 | $1.83 | $25,620.00 |
DisclosureSEC source: 0000899243-19-029185 · doc4.xml · nonDerivative · entry 3 Basta Steven L · CIK 0001417397 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 509,764 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 11, 2019 Filed Dec 13, 2019 21:54 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | Tax withholdingCommon stock | 85,210 | $4.52 | $385,149.20 |
DisclosureSEC source: 0000899243-19-029185 · doc4.xml · nonDerivative · entry 2 Basta Steven L · CIK 0001417397 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 495,764 Read SEC document |
| December 11, 2019 Filed Dec 13, 2019 21:54 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | Exercise / conversionCommon stock | 238,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-029185 · doc4.xml · nonDerivative · entry 1 Basta Steven L · CIK 0001417397 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 580,974 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On July 29, 2019, the Reporting Person was granted 238,800 restricted stock units ("RSUs"), for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. The RSUs were scheduled to vest in two (2) equal annual installments beginning July 29, 2020. The vesting of the RSUs was accelerated in full on December 11, 2019 in connection with the pending transactions contemplated by the Agreement and Plan of Merger entered into on November 10, 2019 among the Issuer, Foamix Pharmaceuticals Ltd and Giants Merger Subsidiary Ltd., a wholly-owned subsidiary of the Issuer, in order to mitigate potential negative tax consequences to both the Issuer and the Reporting Person under Section 280G and 4999 of the Internal Revenue Code. F2 · balance_after: Includes the acquisition of 6,234 shares of the Issuer's common stock pursuant to the Menlo Therapeutics Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase periods of September 1, 2018 through February 28, 2019 and March 1, 2019 through August 31, 2019, which shares were acquired in order to mitigate potential negative tax consequences to both the Issuer and the Reporting Person under Section 280G and 4999 of the Internal Revenue Code. This transaction is exempt under Rule 16b-3(c). Read SEC document |
| December 11, 2019 Filed Dec 16, 2019 17:11 UTC Amendment | Yarrow Bioscience, Inc. MNLO · Entity 6871 | Exercise / conversionNon-Qualified Stock Option · Derivative | 14,000 | $1.83 | $25,620.00 |
DisclosureSEC source: 0000899243-19-029290 · doc4a.xml · derivative · entry 5 Basta Steven L · CIK 0001417397 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 357,641 Underlying: Common Stock · 14,000 shares Expires 2026-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Non-Qualified Stock Option was exercised and the shares were acquired in order to mitigate potential negative tax consequences to both the Issuer and the Reporting Person under Section 280G and 4999 of the Internal Revenue Code. Read SEC document |
| December 11, 2019 Filed Dec 16, 2019 17:11 UTC Amendment | Yarrow Bioscience, Inc. MNLO · Entity 6871 | Exercise / conversionRestricted Stock Units · Derivative | 238,800 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-029290 · doc4a.xml · derivative · entry 4 Basta Steven L · CIK 0001417397 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 238,800 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On July 29, 2019, the Reporting Person was granted 238,800 restricted stock units ("RSUs"), for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. The RSUs were scheduled to vest in two (2) equal annual installments beginning July 29, 2020. The vesting of the RSUs was accelerated in full on December 11, 2019 in connection with the pending transactions contemplated by the Agreement and Plan of Merger entered into on November 10, 2019 among the Issuer, Foamix Pharmaceuticals Ltd and Giants Merger Subsidiary Ltd., a wholly-owned subsidiary of the Issuer, in order to mitigate potential negative tax consequences to both the Issuer and the Reporting Person under Section 280G and 4999 of the Internal Revenue Code. F1 · derivative.exercise_date: On July 29, 2019, the Reporting Person was granted 238,800 restricted stock units ("RSUs"), for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. The RSUs were scheduled to vest in two (2) equal annual installments beginning July 29, 2020. The vesting of the RSUs was accelerated in full on December 11, 2019 in connection with the pending transactions contemplated by the Agreement and Plan of Merger entered into on November 10, 2019 among the Issuer, Foamix Pharmaceuticals Ltd and Giants Merger Subsidiary Ltd., a wholly-owned subsidiary of the Issuer, in order to mitigate potential negative tax consequences to both the Issuer and the Reporting Person under Section 280G and 4999 of the Internal Revenue Code. F1 · derivative.expiration_date: On July 29, 2019, the Reporting Person was granted 238,800 restricted stock units ("RSUs"), for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. The RSUs were scheduled to vest in two (2) equal annual installments beginning July 29, 2020. The vesting of the RSUs was accelerated in full on December 11, 2019 in connection with the pending transactions contemplated by the Agreement and Plan of Merger entered into on November 10, 2019 among the Issuer, Foamix Pharmaceuticals Ltd and Giants Merger Subsidiary Ltd., a wholly-owned subsidiary of the Issuer, in order to mitigate potential negative tax consequences to both the Issuer and the Reporting Person under Section 280G and 4999 of the Internal Revenue Code. Read SEC document |
| December 11, 2019 Filed Dec 16, 2019 17:11 UTC Amendment | Yarrow Bioscience, Inc. MNLO · Entity 6871 | Exercise / conversionCommon stock | 14,000 | $1.83 | $25,620.00 |
DisclosureSEC source: 0000899243-19-029290 · doc4a.xml · nonDerivative · entry 3 Basta Steven L · CIK 0001417397 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 509,764 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 11, 2019 Filed Dec 16, 2019 17:11 UTC Amendment | Yarrow Bioscience, Inc. MNLO · Entity 6871 | Tax withholdingCommon stock | 85,210 | $4.52 | $385,149.20 |
DisclosureSEC source: 0000899243-19-029290 · doc4a.xml · nonDerivative · entry 2 Basta Steven L · CIK 0001417397 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 495,764 Read SEC document |
| December 11, 2019 Filed Dec 16, 2019 17:11 UTC Amendment | Yarrow Bioscience, Inc. MNLO · Entity 6871 | Exercise / conversionCommon stock | 238,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-029290 · doc4a.xml · nonDerivative · entry 1 Basta Steven L · CIK 0001417397 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 580,974 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On July 29, 2019, the Reporting Person was granted 238,800 restricted stock units ("RSUs"), for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. The RSUs were scheduled to vest in two (2) equal annual installments beginning July 29, 2020. The vesting of the RSUs was accelerated in full on December 11, 2019 in connection with the pending transactions contemplated by the Agreement and Plan of Merger entered into on November 10, 2019 among the Issuer, Foamix Pharmaceuticals Ltd and Giants Merger Subsidiary Ltd., a wholly-owned subsidiary of the Issuer, in order to mitigate potential negative tax consequences to both the Issuer and the Reporting Person under Section 280G and 4999 of the Internal Revenue Code. F2 · balance_after: Includes the acquisition of 6,234 shares of the Issuer's common stock pursuant to the Menlo Therapeutics Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase periods of September 1, 2018 through February 28, 2019 and March 1, 2019 through August 31, 2019. This transaction is exempt under Rule 16b-3(c). Read SEC document |
| November 26, 2019 Filed Nov 27, 2019 19:29 UTC | VIVEVE MEDICAL, INC. VIVE · Entity 11899 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 660,000 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001437749-19-023669 · rdgdoc.xml · derivative · entry 1 Basta Steven L · CIK 0001417397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 660,000 Underlying: Common Stock · 660,000 shares Expires 2029-11-25 F1 · derivative.exercise_date: The stock option shall vest and become exercisable in 48 equal monthly installments after November 26, 2019, subject to the Reporting Person's continuous service to the Issuer through each such date. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 18:35 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantRestricted Stock Units · Derivative | 238,800 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-020704 · doc4.xml · derivative · entry 1 Basta Steven L · CIK 0001417397 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,050,100 Underlying: Common Stock · 238,800 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive a share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs shall vest in two (2) equal annual installments beginning July 29, 2020, provided Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest. F3 · derivative.expiration_date: Not Applicable Read SEC document |
| July 29, 2019 Filed Aug 7, 2019 19:30 UTC Amendment | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantRestricted Stock Units · Derivative | 238,800 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-021299 · doc4a.xml · derivative · entry 1 Basta Steven L · CIK 0001417397 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,050,100 Underlying: Common Stock · 238,800 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive a share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs shall vest in two (2) equal annual installments beginning July 29, 2020, provided Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissable Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest. F3 · derivative.expiration_date: Not Applicable Read SEC document |
| May 29, 2019 Filed May 31, 2019 16:31 UTC | VIVEVE MEDICAL, INC. VIVE · Entity 11899 | GrantNon-Qualified Stock Option (Right to Purchase) · Derivative | 35,000 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001437749-19-011163 · rdgdoc.xml · derivative · entry 1 Basta Steven L · CIK 0001417397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2029-05-28 F1 · derivative.exercise_date: The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan (the "Plan") and received 35,000 non-qualified stock options on May 29, 2019 (the "Grant Date"). The non-qualified stock options shall vest in full on the first anniversary of the Grant Date. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 16:34 UTC | VIVEVE MEDICAL, INC. VIVE · Entity 11899 | GrantCommon Stock | 24,199 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-19-006478 · rdgdoc.xml · nonDerivative · entry 1 Basta Steven L · CIK 0001417397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,199 F1 · shares: The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan (the "Plan") and received a restricted stock award of 24,199 shares of common stock on April 1, 2019 (the "Grant Date"). The restricted stock award shall vest in full on the Grant Date. Read SEC document |
| January 15, 2019 Filed Jan 16, 2019 17:07 UTC | VIVEVE MEDICAL, INC. VIVE · Entity 11899 | GrantNon-Qualified Stock Option (Right to Purchase) · Derivative | 35,000 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001437749-19-000932 · rdgdoc.xml · derivative · entry 1 Basta Steven L · CIK 0001417397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2029-01-14 F1 · derivative.exercise_date: The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan (the "Plan") and received 35,000 non-qualified stock options on January 15, 2019 (the "Grant Date"). The non-qualified stock options shall vest in full on the first anniversary of the Grant Date. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 18:42 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantStock Option · Derivative | 141,900 | $0.00 Strike: $5.51 | $0.00 |
DisclosureSEC source: 0001566044-18-000011 · edgardoc.xml · derivative · entry 1 Basta Steven L · CIK 0001417397 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,900 Underlying: Common Stock · 141,900 shares Expires 2028-12-10 F1 · derivative.exercise_date: The shares subject to the option will vest over a period of four years, with 1/48th of the shares subject to the option vesting monthly. Read SEC document |
| September 13, 2018 Filed Sep 14, 2018 14:08 UTC | VIVEVE MEDICAL, INC. VIVE · Entity 11899 | GrantNon-Qualified Stock Options · Derivative | 70,000 | $0.00 Strike: $3.45 | $0.00 |
DisclosureSEC source: 0001437749-18-017040 · rdgdoc.xml · derivative · entry 1 Basta Steven L · CIK 0001417397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2028-09-12 F1 · derivative.exercise_date: The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan and received 70,000 non-qualified stock options on September 13, 2018 (the "Grant Date"). The non-qualified stock options will vest in equal annual installments over three years beginning on the first anniversary of the Grant Date. Read SEC document |
| May 03, 2018 Filed May 4, 2018 16:31 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantStock Option · Derivative | 212,850 | $0.00 Strike: $8.49 | $0.00 |
DisclosureSEC source: 0001209191-18-028118 · doc4.xml · derivative · entry 1 Basta Steven L · CIK 0001417397 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 669,400 Underlying: Common Stock · 212,850 shares Expires 2028-05-02 F1 · derivative.exercise_date: The shares subject to the option will vest over a period of four years, with 1/48th of the shares subject to the option vesting monthly. Read SEC document |
| November 21, 2016 Filed Nov 22, 2016 16:14 UTC | KalVista Pharmaceuticals, Inc. CBYL · Entity 39180 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,125 | $0.00 Strike: $7.84 | $0.00 |
DisclosureSEC source: 0001140361-16-087582 · doc1.xml · derivative · entry 4 Basta Steven L · CIK 0001417397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,125 shares Expires 2023-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were completed pursuant to the consummation of the actions contemplated in that certain Share Purchase Agreement, dated as of June 15, 2016, by and among Carbylan, KalVista Pharmaceuticals Ltd. ("KalVista"), the shareholders of KalVista, and T. Andrew Crockett as the Seller Representative (the "Transaction"), and reflect a 14 to 1 reverse stock split completed immediately prior to the closing of the Transaction. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.